Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications

por Mahmood, Niaz, Mihalcioiu, Catalin, Rabbani, Shafaat A.
Publicado en Front Oncol (2018)

Abscopal Effect in a Stage IV Melanoma Patient who Progressed on Pembrolizumab

por Tsui, James M, Mihalcioiu, Catalin, Cury, Fabio L
Publicado en Cureus (2018)

Enhanced Anticancer Effect of a Combination of S-adenosylmethionine (SAM) and Immune Checkpoint Inhibitor (ICPi) in a Syngeneic Mouse Model of Advanced Melanoma

por Mehdi, Ali, Attias, Mikhael, Mahmood, Niaz, Arakelian, Ani, Mihalcioiu, Catalin, Piccirillo, Ciriaco A., Szyf, Moshe, Rabbani, Shafaat Ahmed
Publicado en Front Oncol (2020)

A pilot study using dynamic contrast enhanced-MRI as a response biomarker of the radioprotective effect of memantine in patients receiving whole brain radiotherapy

por Wong, Philip, Leppert, Ilana R., Roberge, David, Boudam, Karim, Brown, Paul D., Muanza, Thierry, Pike, G. Bruce, Chankowsky, Jeffrey, Mihalcioiu, Catalin
Publicado en Oncotarget (2016)

Pilot study investigating the prognostic significance of thymidine phosphorylase expression in patients with metastatic breast cancer: a single institution retrospective analysis

por Tedeschi, Anna Lisa, Eslami, Zohreh, Garoufalis, Evgenia, Saleh, Ramy R, Omeroglu, Atilla, Altinel, Gulbeyaz, Ait-Tihyaty, Maria, Jean-Claude, Bertrand, Mihalcioiu, Catalin
Publicado en Onco Targets Ther (2015)

DNA methylation signatures of breast cancer in peripheral T-cells

por Parashar, Surabhi, Cheishvili, David, Mahmood, Niaz, Arakelian, Ani, Tanvir, Imrana, Khan, Haseeb Ahmed, Kremer, Richard, Mihalcioiu, Catalin, Szyf, Moshe, Rabbani, Shafaat A.
Publicado en BMC Cancer (2018)

A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER...

por Chia, Stephen K., Ellard, Susan L., Mates, Mihaela, Welch, Stephen, Mihalcioiu, Catalin, Miller, Wilson H., Gelmon, Karen, Lohrisch, Caroline, Kumar, Vikaash, Taylor, Sara, Hagerman, Linda, Goodwin, Rachel, Wang, Tao, Sakashita, Shingo, Tsao, Ming S., Eisenhauer, Elizabeth, Bradbury, Penelope
Publicado en Breast Cancer Res (2017)

Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer

por Cavallone, Luca, Aguilar-Mahecha, Adriana, Lafleur, Josiane, Brousse, Susie, Aldamry, Mohammed, Roseshter, Talia, Lan, Cathy, Alirezaie, Najmeh, Bareke, Eric, Majewski, Jacek, Ferrario, Cristiano, Hassan, Saima, Discepola, Federico, Seguin, Carole, Mihalcioiu, Catalin, Marcus, Elizabeth A., Robidoux, André, Roy, Josée-Anne, Pelmus, Manuela, Basik, Mark
Publicado en Sci Rep (2020)

Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma

por Long, Georgina V, Atkinson, Victoria, Ascierto, Paolo A, Brady, Benjamin, Dutriaux, Caroline, Maio, Michele, Mortier, Laurent, Hassel, Jessica C, Rutkowski, Piotr, McNeil, Catriona, Kalinka-Warzocha, Ewa, Savage, Kerry J, Hernberg, Micaela, Lebbé, Celeste, Charles, Julie, Mihalcioiu, Catalin, Chiarion-Sileni, Vanna, Mauch, Cornelia, Schmidt, Henrik, Schadendorf, Dirk, Gogas, Helen, Horak, Christine, Sharkey, Brian, Waxman, Ian M, Robert, Caroline
Publicado en J Transl Med (2015)

Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial

por Ascierto, Paolo A., Long, Georgina V., Robert, Caroline, Brady, Benjamin, Dutriaux, Caroline, Di Giacomo, Anna Maria, Mortier, Laurent, Hassel, Jessica C., Rutkowski, Piotr, McNeil, Catriona, Kalinka-Warzocha, Ewa, Savage, Kerry J., Hernberg, Micaela M., Lebbé, Celeste, Charles, Julie, Mihalcioiu, Catalin, Chiarion-Sileni, Vanna, Mauch, Cornelia, Cognetti, Francesco, Ny, Lars, Arance, Ana, Svane, Inge Marie, Schadendorf, Dirk, Gogas, Helen, Saci, Abdel, Jiang, Joel, Rizzo, Jasmine, Atkinson, Victoria
Publicado en JAMA Oncol (2018)

Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma

por Robert, Caroline, Long, Georgina V., Brady, Benjamin, Dutriaux, Caroline, Di Giacomo, Anna Maria, Mortier, Laurent, Rutkowski, Piotr, Hassel, Jessica C., McNeil, Catriona M., Kalinka, Ewa Anna, Lebbé, Céleste, Charles, Julie, Hernberg, Micaela M., Savage, Kerry J., Chiarion-Sileni, Vanna, Mihalcioiu, Catalin, Mauch, Cornelia, Arance, Ana, Cognetti, Francesco, Ny, Lars, Schmidt, Henrik, Schadendorf, Dirk, Gogas, Helen, Zoco, Jesús, Re, Sandra, Ascierto, Paolo A., Atkinson, Victoria
Publicado en J Clin Oncol (2020)